Results 61 to 70 of about 1,185,869 (358)
Circulating histones as clinical biomarkers in critically ill conditions
FEBS Letters, EarlyView.Circulating histones are emerging as promising biomarkers in critical illness due to their diagnostic, prognostic, and therapeutic potential. Detection methods such as ELISA and mass spectrometry provide reliable approaches for quantifying histone levels in plasma samples.
José Luis García‐Gimenez +17 more
wiley +1 more source
Neutralization of budded Autographa californica NPV by a monoclonal antibody: identification of the target antigen. [PDF]
, 1984 A neutralizing monoclonal antibody of the budded phenotype of Autographa californica nuclear polyhedrons virus did not react with the occluded form of the virus as determined by neutralization, ELISA, and indirect immunoperoxidase staining.
Faulkner, P +3 more
core
Insights into neutralization of animal viruses gained from study of influenza virus [PDF]
, 1991 It has long been known that the binding of antibodies to viruses can result in a loss of infectivity, or neutralization, but little is understood of the mechanism or mechanisms of this process.
Colonno +17 more
core +2 more sources
Cell Discovery, 2023 SARS-CoV-2 Omicron subvariants have demonstrated extensive evasion from monoclonal antibodies (mAbs) developed for clinical use, which raises an urgent need to develop new broad-spectrum mAbs.
Yanqun Wang +40 more
doaj +1 more source
Single‐cell insights into the role of T cells in B‐cell malignancies
FEBS Letters, EarlyView.Single‐cell technologies have transformed our understanding of T cell–tumor cell interactions in B‐cell malignancies, revealing new T‐cell subsets, functional states, and immune evasion mechanisms. This Review synthesizes these findings, highlighting the roles of T cells in pathogenesis, progression, and therapy response, and underscoring their ...
Laura Llaó‐Cid
wiley +1 more source
Pharmacokinetics of Monoclonal Antibodies
CPT: Pharmacometrics & Systems Pharmacology, 2017 Monoclonal antibodies (mAbs) have developed in the last two decades into the backbone of pharmacotherapeutic interventions in a variety of indications, with currently more than 40 mAbs approved by the US Food and Drug Administration, and several dozens more in clinical development. This tutorial will review major drug disposition processes relevant for
Bernd Meibohm, Josiah T. Ryman
openaire +3 more sources
Clathrin structure characterized with monoclonal antibodies. I. Analysis of multiple antigenic sites. [PDF]
, 1985 Three monoclonal antibodies that react with previously undefined antigenic determinants on the clathrin molecule have been produced and characterized. They were isolated from a fusion between myeloma cells and popliteal lymphocytes from SJL mice that had
Brodsky, Frances
core
Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. [PDF]
, 1985 Autoimmune NZB/NZW mice were treated with weekly injections of monoclonal antibody (mAb) to L3T4, an antigen expressed on a distinct subpopulation of T cells that respond to class II major histocompatibility antigens.
Seaman, WE, Wofsy, D
core +1 more source
Antibody Response to Human Extracellular HER2 Subdomain Proteins in Mice [PDF]
Iranian Journal of Immunology, 2017 Background: In addition to passive immunotherapy using anti-HER2 monoclonal antibodies, active immunotherapy via HER2 targeting is an interesting approach to inducing specific anti-tumor immune responses.
Fateme Sadri-Ardalani +8 more
doaj
A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo
Frontiers in Immunology, 2021 Overexpression of HER2 has been reported in many types of cancer, making it a perfect candidate for targeted immunotherapy. The combination of two FDA approved monoclonal antibodies (mAbs), trastuzumab and pertuzumab, has more robust anti-tumor activity ...
Mehdi Mohammadi +11 more
doaj +1 more source